Eun Ji Kim

Eun Ji Kim

Auto-generated profile, based on publicly available information

Eun Ji Kim

Independent Researcher

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
NCNam Woo Cho
Nam Woo Cho
SGSophia M. Guldberg
Sophia M. Guldberg
BNBarzin Y. Nabet
Barzin Y. Nabet
JYJie Zeng Yu
Jie Zeng Yu
EKEun Ji Kim
Eun Ji Kim
MSMatthew H. Spitzer
Matthew H. Spitzer
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.

3 February 2025
Verified
Other
Open access
NCNam Woo Cho
Nam Woo Cho
SGSophia M. Guldberg
Sophia M. Guldberg
BNBarzin Y. Nabet
Barzin Y. Nabet
JYJie Zeng Yu
Jie Zeng Yu
EKEun Ji Kim
Eun Ji Kim
MSMatthew H. Spitzer
Matthew H. Spitzer
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.